的基因疗法是否已经准备好用于诊所?
James S Street1, Yichen Qiu1, Gabriele Lignani1
1Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom.
Epilepsy currents
|September 4, 2023
概括
基因疗法对治疗有前途,许多临床前研究正在进入临床试验. 未来的研究将确定这些基因治疗对耐火性患者的潜力.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 治疗研究越来越多地关注基因疗法.
- 现在有几种基因疗法正在临床试验中,用于单基因和焦点耐火性.
研究的目的:
- 为提供对前临床基因疗法研究的概述.
- 在动物模型中突出显示了减轻发作的疗法和临床转化潜力.
主要方法:
- 对的基因疗法进行临床前研究的审查.
- 专注于针对疾病原因或症状的治疗方法.
- 对临床转化潜力的评估.
主要成果:
- 基因疗法的临床前研究显著增加.
- 一些疗法的进展到临床试验.
- 在选择疗法的动物模型中证明了发作的减少.
结论:
- 临床前研究表明,在中基因疗法具有显著的潜力.
- 这些疗法的临床转化是一个关键的重点.
- 未来几年对于评估的遗传治疗疗法的疗效至关重要.
相关概念视频
Gene Therapy
25.5K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.5K
Arteries of the Lower Limbs
212
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
212
What is Genetic Engineering?
74.3K
Overview
74.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
341
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
341
Genetic Screens
5.0K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.0K
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


